While antagonistic interactions were determined in the OCT2-positive cancer cells, it should be noted that the combination can still be beneficial to patients with OCT2-positive tumors in suppressing CIS-induced nephrotoxicity, especially at higher doses or for a longer duration and thereby benefit from the anticancer activity of CIS. Here, SLC22A2 is linked to in situ carcinoma.